QNCX

Quince Therapeutics Inc. (QNCX) | Rumor.io

Quince Therapeutics

QNCX

Attention (50-day avg)0%

Attention rank (50-day avg)#2,469

Bullish sentiment (50-day avg)80%

Price to earnings ratio-0.09

Market capitalization29.5M

Earnings per share-210.8

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-84M

Social

What share of all stock conversation is about QNCX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% +0

Sep 10

Quince Therapeutics, in partnership with Orphai Therapeutics, is addressing unmet needs in treating PH-ILD and SAPH conditions with inhaled Rapamycin (LAM-001) via mTOR receptor delivery.
The treatment has shown promise in reversing (BOS) and addressing the vocal unmet need for over a decade by top transplant surgeons.
Quince Therapeutics has an operational runway until 2028, with phase data expected in 2027 and 2028.

Generated by AI

Sentiment

Of the messages about QNCX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +17.86	82.78% -8.54
Bearish	—	—	0% -17.86	17.22% +8.54

Bullish· Apr 16

The short float for $QNCX is jumping, indicating a good possibility for a squeeze.
Closing above $1.35 would be a positive sign, and the company has made significant progress with its reverse split and debt retirement.
The stock has the potential to run high after a merger or buyout news, with some analysts predicting a price target of $4 if it breaks above $2.5.

Bearish· May 19

Quince Therapeutics, Inc. ($QNCX) has a high risk of being delisted due to low investor IQ.
The company's management has failed to capitalize on opportunities, leading to a loss of investor confidence and a potential decline in stock value.
The reverse merger with OrphAI has diluted the value of $QNCX shares, with the new company's pipeline and management potentially leading to a further decrease in value.

Generated by AI

Topics

Of the messages about QNCX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	42.86%	75.76%	27.28%
Analysts	—	57.14%	12.12%	29.68%
Technical Analysis	—	0%	0%	23.45%
Earnings	—	0%	0%	0.55%
Controversies	—	0%	12.12%	0.08%
Macro	—	0%	0%	18.97%

Announcements· Apr 8

Quince Therapeutics (QNCX) has settled its $16.4 million debt with the European Investment Bank for $5.5 million, removing a financial "overhang" and making the company more attractive to potential merger partners.
The company is actively exploring a reverse merger as part of a broader evaluation of strategic alternatives, with a specific private company deal not yet finalized.
Quince retains approximately $17-18 million in cash after debt payment and is an ideal partner for a private biotechnology company in late clinical phase that needs capital to complete its studies.

Technical Analysis· Apr 8

$QNCX has a strong chance of breaking through the $0.30/$0.28 level, with a possible target of $0.4.
A close above $0.4350 could lead to a price increase to $0.47/$0.48 or higher.
$QNCX needs to hold above $0.36 to continue its rally, with a potential target of $0.60 and $0.90.

Generated by AI

Community

Of the messages about QNCX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	93.33%	58.02%	19.49%
Newcomers	0%	6.67%	41.98%	80.51%

Regulars· Apr 8

Quince Therapeutics, Inc. ($QNCX) has eliminated $16.4M of outstanding debt through a settlement payment of $5.5M.
$QNCX's chart is showing a clean uptrending pattern, with a recent break above the VWAP and a potential resistance line at 0.36.
The stock's short volume has been significant, with 57.44% of today's total reported volume being short, and an average short volume of 57.74% over the past 30 days.

Newcomers· Jul 29

The newcomer is excited about the potential of Quince Therapeutics, Inc. ($QNCX) to reach $100 a share, driven by its ultra-low free float and recent upgrades by Oppenheimer.
The asset is perceived as being undervalued, with the price expected to increase significantly, possibly even parabolically, due to its low free float and recent stock performance.
The newcomer is calling for the company to take action, specifically to acquire LAM-001 and partner with big pharma companies to maximize shareholder value and increase the stock price.

Generated by AI

News

Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious, underserved diseases, today announced that it will host a virtual key opinion leader (KOL) event on Monday, September 28, 2026 from 12:30-2:00 PM ET. The event will feature PH-ILD experts Aaron B. Waxman, MD, PhD (Brigham and Women's Hospital) and Paul Yu, MD, PhD (Massach

12d agoYahoo Finance

Quince Therapeutics at Cantor conference: inhaled rapamycin gains traction

20d agoInvesting.com

Quince Therapeutics Faces Nasdaq Listing Compliance Challenges

Detailed price information for Quince Therapeutics Inc (QNCX-Q) from The Globe and Mail including charting and trades.

24d agoThe Globe and Mail

Also Discussed

Investors talking about QNCX also mention

#	Name	Attention
1	Linkers Industries LimitedLNKS	0%0
2	SGN - Signing Day Sports, Inc.	——
3	AMTI - Applied Molecular Transport Inc.	——
4	UOKA - MDJM Ltd	——
5	Jet.AI Inc.JTAI	0%new
6	Battalion Oil CorpBATL	0.03%+0.01
7	Xiao-I Corporation American Depositary SharesAIXI	0.01%+0.01
8	UTime LimitedWTO	0%0
9	Decent Holding Inc. Class A Ordinary SharesDXST	0.02%new
10	Onfolio Holdings, Inc.ONFO	0%-0.05

Quince Therapeutics Inc.

Healthcare
Biotechnology

Quince Therapeutics Inc. is a biotechnology company focused on developing and commercializing therapies for serious rare diseases. The company’s current work centers on its proprietary Autologous Intracellular Drug Encapsulation platform, designed to deliver treatments using a patient’s own red blood cells. Its lead development programs target rare pediatric neurodegenerative and pulmonary conditions, reflecting a focus on underserved areas with limited treatment options. Quince Therapeutics serves the specialty biopharmaceutical market by advancing disease-modifying therapies intended for patients with debilitating disorders, while also building capabilities in drug-device combination technologies and clinical-stage development.

Website

Location

611 Gateway Boulevard

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about QNCX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% +0

Sep 10

Quince Therapeutics, in partnership with Orphai Therapeutics, is addressing unmet needs in treating PH-ILD and SAPH conditions with inhaled Rapamycin (LAM-001) via mTOR receptor delivery.
The treatment has shown promise in reversing (BOS) and addressing the vocal unmet need for over a decade by top transplant surgeons.
Quince Therapeutics has an operational runway until 2028, with phase data expected in 2027 and 2028.

Generated by AI

Sentiment

Of the messages about QNCX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +17.86	82.78% -8.54
Bearish	—	—	0% -17.86	17.22% +8.54

Bullish· Apr 16

The short float for $QNCX is jumping, indicating a good possibility for a squeeze.
Closing above $1.35 would be a positive sign, and the company has made significant progress with its reverse split and debt retirement.
The stock has the potential to run high after a merger or buyout news, with some analysts predicting a price target of $4 if it breaks above $2.5.

Bearish· May 19

Quince Therapeutics, Inc. ($QNCX) has a high risk of being delisted due to low investor IQ.
The company's management has failed to capitalize on opportunities, leading to a loss of investor confidence and a potential decline in stock value.
The reverse merger with OrphAI has diluted the value of $QNCX shares, with the new company's pipeline and management potentially leading to a further decrease in value.

Generated by AI

Topics

Of the messages about QNCX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	42.86%	75.76%	27.28%
Analysts	—	57.14%	12.12%	29.68%
Technical Analysis	—	0%	0%	23.45%
Earnings	—	0%	0%	0.55%
Controversies	—	0%	12.12%	0.08%
Macro	—	0%	0%	18.97%

Announcements· Apr 8

Quince Therapeutics (QNCX) has settled its $16.4 million debt with the European Investment Bank for $5.5 million, removing a financial "overhang" and making the company more attractive to potential merger partners.
The company is actively exploring a reverse merger as part of a broader evaluation of strategic alternatives, with a specific private company deal not yet finalized.
Quince retains approximately $17-18 million in cash after debt payment and is an ideal partner for a private biotechnology company in late clinical phase that needs capital to complete its studies.

Technical Analysis· Apr 8

$QNCX has a strong chance of breaking through the $0.30/$0.28 level, with a possible target of $0.4.
A close above $0.4350 could lead to a price increase to $0.47/$0.48 or higher.
$QNCX needs to hold above $0.36 to continue its rally, with a potential target of $0.60 and $0.90.

Generated by AI

Community

Of the messages about QNCX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	93.33%	58.02%	19.49%
Newcomers	0%	6.67%	41.98%	80.51%

Regulars· Apr 8

Quince Therapeutics, Inc. ($QNCX) has eliminated $16.4M of outstanding debt through a settlement payment of $5.5M.
$QNCX's chart is showing a clean uptrending pattern, with a recent break above the VWAP and a potential resistance line at 0.36.
The stock's short volume has been significant, with 57.44% of today's total reported volume being short, and an average short volume of 57.74% over the past 30 days.

Newcomers· Jul 29

The newcomer is excited about the potential of Quince Therapeutics, Inc. ($QNCX) to reach $100 a share, driven by its ultra-low free float and recent upgrades by Oppenheimer.
The asset is perceived as being undervalued, with the price expected to increase significantly, possibly even parabolically, due to its low free float and recent stock performance.
The newcomer is calling for the company to take action, specifically to acquire LAM-001 and partner with big pharma companies to maximize shareholder value and increase the stock price.

Generated by AI

Quince Therapeutics

Social

Sep 10

Bullish· Apr 16

Bearish· May 19

Announcements· Apr 8

Technical Analysis· Apr 8

Regulars· Apr 8

Newcomers· Jul 29

Citizens reiterates Quince Therapeutics stock rating on therapy potential

Rodman & Renshaw initiates Quince Therapeutics stock with buy rating

Citizens upgrades Quince Therapeutics stock rating on rare disease pipeline

Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026

Quince Therapeutics at Cantor conference: inhaled rapamycin gains traction

Quince Therapeutics Faces Nasdaq Listing Compliance Challenges

Also Discussed

Quince Therapeutics Inc.

Company Information

Location

Citizens reiterates Quince Therapeutics stock rating on therapy potential

Rodman & Renshaw initiates Quince Therapeutics stock with buy rating

Citizens upgrades Quince Therapeutics stock rating on rare disease pipeline

Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026

Quince Therapeutics at Cantor conference: inhaled rapamycin gains traction

Quince Therapeutics Faces Nasdaq Listing Compliance Challenges

Also Discussed

Social

Sep 10

Bullish· Apr 16

Bearish· May 19

Announcements· Apr 8

Technical Analysis· Apr 8

Regulars· Apr 8

Newcomers· Jul 29